AIMM Therapeutics

AIMM therapeutics B.V. was established in 2004 with the goal to develop therapeutic and prophylactic human monoclonal antibodies. AIMM's capitalizes on a breakthrough proprietary technology to isolate human monoclonal antibodies for prevention and treatment of infectious diseases, inflammatory diseases and cancer. AIMM employs a team of 20 scientists and research technicians.

We have generated a series of monoclonal antibodies specific for several pathogenic viruses and bacteria and several types of cancer. The current pipeline includes antibodies against respiratory syncytial virus, influenza virus and staphylococcus aureus, AML, Melanoma and some undisclosed cancer types.

AIMM has received financing from its principal investor, the AMC and from the Life Sciences Fund Amsterdam.